News & Updates
Filter by Specialty:
Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.
Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
25 Jun 2022
SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risk of serious hyperkalaemia (serum potassium [K+] ≥6.0 mmol/L) without increasing the risk of hypokalaemia (serum K+ ≤3.5 mmol/L) in individuals with type 2 diabetes (T2D) at high cardiovascular (CV) risk, or in those with chronic kidney disease (CKD), a meta-analysis has shown.
SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
23 Jun 2022
NAFLD linked to heightened type 2 diabetes risk
Children with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of type 2 diabetes, a study reports. Other risk factors for T2D include severity of liver histology, body mass index, and female sex.
NAFLD linked to heightened type 2 diabetes risk
22 Jun 2022
Rapid childhood growth rate tied to elevated risk of islet autoimmunity, T1D development
Children who grow in height fast appears to have a higher risk of islet autoimmunity (IAA) and rapid progression to type 1 diabetes (T1D), a study has found.